AdAlta Opens FDA Pathway for EW-001 Mesothelioma CAR-T
AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.
- FDA accepts pre-IND meeting request for EW-001
- Meeting to address manufacturing, non-clinical studies and Phase 1 design
- Australian manufacturing transfer and clinical protocol preparation completed to briefing stage
- FDA meeting scheduled for 3 November US time
- EW-001 remains unapproved and clinical data are from early Chinese studies
FDA Meeting Moves EW-001 Into Regulatory Review
AdAlta Limited (ASX:1AD) has cleared an important procedural hurdle for EW-001, with the US Food and Drug Administration accepting the company’s request for a pre-IND meeting on its CAR-T therapy for advanced mesothelioma and other mesothelin-expressing cancers. The meeting does not amount to regulatory approval or permission to begin clinical trials, but it gives AdAlta a formal opportunity to test its development plan before committing to the costliest parts of the programme.
The virtual meeting is scheduled for 3 November 2026 US time, or 4 November in Australia. The FDA is expected to issue written minutes two to four weeks later, although AdAlta says the amount of additional work required will depend on the scope of the regulator’s feedback.
Three Workstreams Support the Briefing
The significance of the announcement lies less in the meeting acceptance itself than in the preparation behind it. AdAlta says it has reviewed hundreds of documents transferred by development partner Shanghai Cell Therapy Group, including manufacturing methods, quality testing, laboratory and animal studies, and patient-level results from investigator-initiated trials in China.
That material has been combined with a draft Phase 1 protocol developed with Australian CAR-T and mesothelioma clinicians, covering patient eligibility, dosing, safety monitoring and clinical outcomes. In parallel, work with Melbourne contract manufacturer Cell Therapies has focused on transferring and optimising the process needed to produce EW-001 in Australia under standards intended to meet FDA expectations.
AdAlta’s regulatory advisers, Dark Horse Consulting, are supporting the briefing document and the meeting. The FDA will be asked to comment on whether the proposed Australian manufacturing process is comparable and adequately tested, which remaining laboratory and animal studies are needed, and how the Phase 1 trial should handle patient selection, starting dose, escalation and safety monitoring.
Early Clinical Signal Still Needs Western Validation
EW-001 is an experimental, first-in-class CAR-T therapy engineered to target mesothelin, a protein expressed in several cancers, while also producing a checkpoint inhibitor intended to help the cells withstand tumour defences. In early studies of relapsed or advanced mesothelioma patients in China, AdAlta reports up to a 50% overall response rate and up to a 20% complete response rate. Two complete responders have reached one- and two-year survival milestones without evidence of recurrence, according to the company.
Those findings remain early clinical evidence from China, and EW-001 has not received regulatory approval for commercial launch anywhere in the world. The forthcoming FDA feedback will therefore be important not only for the trial design but also for determining how much of the existing data can support an eventual US Investigational New Drug submission, and what additional work is required before a Phase 1 study can proceed.
Bottom Line?
The next meaningful data point is not the meeting acceptance but the FDA’s written feedback, which will show how much further manufacturing, non-clinical and clinical work EW-001 needs before an IND submission becomes realistic.
Questions in the middle?
- How much of SHcell’s Chinese manufacturing and clinical evidence will the FDA accept for the US development pathway?
- Will the regulator require additional animal or laboratory studies before Phase 1 recruitment can begin?
- What changes to manufacturing or trial design could affect AdAlta’s funding and partnering requirements?
